Safety and bioequivalency of three formulations of respiratory syncytial virus-enriched immunoglobulin. - Wikidata - awgldk - TriplyDB

Safety and bioequivalency of three formulations of respiratory syncytial virus-enriched immunoglobulin.

Safety and bioequivalency of three formulations of respiratory syncytial virus-enriched immunoglobulin.

http://www.wikidata.org/entity/Q35112303

about

Controlled-release and local delivery of therapeutic antibodies.Respiratory syncytial virus immune globulin intravenous.

P2860

Q35842644-B8B8BECF-8BD6-49ED-8FA8-37394CBBBD75 Q41316287-FEF2076B-8232-4B14-84D2-E608FFDDCE1F

P2860

Safety and bioequivalency of three formulations of respiratory syncytial virus-enriched immunoglobulin.

http://www.wikidata.org/entity/Q35112303

description

1995 nî lūn-bûn

@nan

1995 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

1995 թվականի մարտին հրատարակված գիտական հոդված

@hy

1995年の論文

@ja

1995年論文

@yue

1995年論文

@zh-hant

1995年論文

@zh-hk

1995年論文

@zh-mo

1995年論文

@zh-tw

1995年论文

@wuu

name

Safety and bioequivalency of t ...... virus-enriched immunoglobulin.

@ast

Safety and bioequivalency of t ...... virus-enriched immunoglobulin.

@en

type

label

Safety and bioequivalency of t ...... virus-enriched immunoglobulin.

@ast

Safety and bioequivalency of t ...... virus-enriched immunoglobulin.

@en

prefLabel

Safety and bioequivalency of t ...... virus-enriched immunoglobulin.

@ast

Safety and bioequivalency of t ...... virus-enriched immunoglobulin.

@en

P1433

Q35112303-42FAD37D-D451-4648-A4C8-E1ACCA5B013B

P1476

Q35112303-5505C4C8-9327-42F8-8141-4B898A6F1E35

P2093

Q35112303-21E31796-9BB6-423B-B3C8-B4DCE9F973D9

Q35112303-2A4BCE33-8631-4862-9E67-5F0CDA0ACF76

Q35112303-541E91C1-5FD4-40FC-AAB3-A43990D4F211

Q35112303-6549D9C7-16BC-43FD-A1AA-ACD876792E88

Q35112303-7A4B3008-4AB6-4EBF-A91A-0871C3014D44

Q35112303-91BF030D-3BC7-40DC-B58A-14567FA50AC7

Q35112303-ADE9F980-F0C6-4CA5-8B44-BB772F8043DE

Q35112303-CBD2771B-41E7-4BCE-B1E4-BD5D6420AE03

Q35112303-E9CA125E-BCEC-4BBB-8C91-3B03AA68200A

P2860

Q35112303-05C0656A-B73C-40AD-9DF5-6EC5601B2BB9

Q35112303-28A2DBBF-8874-4610-9196-7F9C851D6297

Q35112303-32658CFE-F607-45F0-B118-B41E7EEAB599

Q35112303-3BB24BBB-C17B-4D02-B8D5-B5A2DA1A0C87

Q35112303-4EE14888-4827-4DB1-AB7B-87DC1FB66145

Q35112303-508B9FC4-EB1D-4ABE-A6B5-DB6BEF90AC8F

Q35112303-E4F814F2-75EE-4627-91BC-1AA73B33531F

Q35112303-F40FF027-FA53-4B18-BE2C-0401EF5B9552

Q35112303-FB140E2E-7E70-43A0-84EE-44CD21AC98A0

P304

Q35112303-FB111D81-6500-4146-8AE5-D1E735AF1E0E

P31

Q35112303-2448EEAD-2731-48AF-AC36-5D777B6B645B

P356

Q35112303-E03AF63B-E318-4F03-A028-473B6906912D

P407

Q35112303-C625131C-1440-49E3-852B-F3FC4A7B6C4D

P433

Q35112303-4C2C2F74-C586-486E-BAAE-DB52C7169E31

P478

Q35112303-BB6E32B6-3454-4115-AC99-BF3D45E9C448

P577

Q35112303-A1FECB3C-3860-42AB-AB76-B54B6BF5EF75

P5875

Q35112303-1CE34E4F-BE7F-4BC5-8B50-919FC7207788

P698

Q35112303-A818435F-15EF-426F-A8E1-E0CF387CBB55

P932

Q35112303-CA1127E3-DFA3-48F4-AAAB-E0AF3D993C76

P356

P1433

Antimicrobial Agents and Chemotherapy

P1476

Safety and bioequivalency of t ...... virus-enriched immunoglobulin.

@en

P2093

A A Kramer

http://www.w3.org/2001/XMLSchema#string

E A Simoes

http://www.w3.org/2001/XMLSchema#string

G R Siber

http://www.w3.org/2001/XMLSchema#string

J Arrobio

http://www.w3.org/2001/XMLSchema#string

J R Groothuis

http://www.w3.org/2001/XMLSchema#string

M V Lehr

http://www.w3.org/2001/XMLSchema#string

R C Welliver

http://www.w3.org/2001/XMLSchema#string

V G Hemming

http://www.w3.org/2001/XMLSchema#string

W J Rodriguez

http://www.w3.org/2001/XMLSchema#string

P2860

Comparison of antibody concentrations and protective activity of respiratory syncytial virus immune globulin and conventional immune globulin.

Protective activity of a human respiratory syncytial virus immune globulin prepared from donors screened by microneutralization assay.

Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. The Respiratory Syncytial Virus Immune Globulin Study Group.

Use of intravenous gamma globulin to passively immunize high-risk children against respiratory syncytial virus: safety and pharmacokinetics. The RSVIG Study Group.

Quantitative aspects of passive immunity to respiratory syncytial virus infection in infant cotton rats

Risk of respiratory syncytial virus infection for infants from low-income families in relationship to age, sex, ethnic group, and maternal antibody level.

Epidemiology of respiratory syncytial virus infection in Washington, D.C. 3. Composite analysis of eleven consecutive yearly epidemics.

Epidemiology of respiratory syncytial virus infection in Washington, D.C. II. Infection and disease with respect to age, immunologic status, race and sex.

Respiratory syncytial virus infection in children with bronchopulmonary dysplasia.

P304

668-671

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/AAC.39.3.668

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

39

http://www.w3.org/2001/XMLSchema#string

P577

1995-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

15405076

http://www.w3.org/2001/XMLSchema#string

P698

7793870

http://www.w3.org/2001/XMLSchema#string

P932

162602

http://www.w3.org/2001/XMLSchema#string